Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships. 

The round, which includes Caris Life Sciences Inc.’s first equity financing from external investors, comes three weeks after the company appointed Brian Lamon as chief business officer and head of biopharma business development. Lamon joined Caris from Bristol Myers Squibb Co. (NYSE:BMY), where he served as VP, development lead, genitourinary malignancies, oncology development. ...